IMMP Stock Overview
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Immutep Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$2.59 |
| 52 Week High | AU$3.90 |
| 52 Week Low | AU$1.50 |
| Beta | 1.83 |
| 1 Month Change | 3.60% |
| 3 Month Change | 21.03% |
| 1 Year Change | 57.93% |
| 3 Year Change | -23.15% |
| 5 Year Change | 40.76% |
| Change since IPO | -93.55% |
Recent News & Updates
Recent updates
Immutep stock climbs on FDA fast track status for eftilagimod to treat lung cancer subtype
Oct 04Immutep secures €1.8M cash in French government's research tax credit
Sep 23Immutep gets Japanese patent for immunotherapy eftilagimod alpha combo
Aug 30Immutep gets Japanese patent related to autoimmune disease drug candidate IMP761
Jul 06Immutep: Australian Immune-Focused Company, Pureplay LAG3 Player
Jun 12Immutep - LAG3 Checkpoint Receives First FDA Approval; Positive For This LAG3 Pure Play
Mar 21Immutep expands the evaluation of efti into a triple combination therapy, shares down 12%
Jun 21Immutep reveals anti-LAG-3 research program
Jun 08Immutep jumps 9% on Chinese patent for efti in chemo-immunotherapy combination
May 26Immutep completes recruitment in efti mid-stage study in head & neck cancer
Jan 07Immutep secures U.S. patent for Eftilagimod Alpha
Dec 29Immutep +72% after breast cancer trial shows promising survival data
Dec 09Immutep to enroll additional patients in mid-stage study with its lead cancer program
Nov 19Immutep rallies on Australian patent grant for IMP701 antibody
Nov 09Shareholder Returns
| IMMP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 14.6% | 1.0% | 1.2% |
| 1Y | 57.9% | 0.7% | 24.9% |
Return vs Industry: IMMP exceeded the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: IMMP exceeded the US Market which returned 24.7% over the past year.
Price Volatility
| IMMP volatility | |
|---|---|
| IMMP Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IMMP has not had significant price volatility in the past 3 months.
Volatility Over Time: IMMP's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | Marc Voigt | www.immutep.com |
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease.
Immutep Limited Fundamentals Summary
| IMMP fundamental statistics | |
|---|---|
| Market cap | US$347.79m |
| Earnings (TTM) | -US$26.33m |
| Revenue (TTM) | US$2.56m |
136.1x
P/S Ratio-13.2x
P/E RatioIs IMMP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMMP income statement (TTM) | |
|---|---|
| Revenue | AU$3.93m |
| Cost of Revenue | AU$37.72m |
| Gross Profit | -AU$33.79m |
| Other Expenses | AU$6.71m |
| Earnings | -AU$40.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.034 |
| Gross Margin | -859.57% |
| Net Profit Margin | -1,030.32% |
| Debt/Equity Ratio | 0.8% |
How did IMMP perform over the long term?
See historical performance and comparison